Comparative Pharmacology
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus RECORLEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus RECORLEV.
LEVOTHYROXINE SODIUM vs RECORLEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic T4 hormone that is deiodinated to T3, which binds to thyroid hormone receptors in the nucleus, regulating gene transcription and increasing metabolic rate.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
Initial adult dose: 25-50 mcg orally once daily, titrated by 12.5-25 mcg every 6-8 weeks based on TSH. Usual maintenance: 1.6 mcg/kg/day. Route: oral; IV dose is 50% of oral dose.
150 mg orally twice daily with a high-fat meal.
None Documented
None Documented
6-7 days (euthyroid); prolonged in hypothyroidism (9-10 days) and shortened in hyperthyroidism (3-4 days).
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
Renal (approximately 50% as unchanged drug and conjugates); fecal (biliary excretion of conjugates, ~20-30%); minor pulmonary and dermal routes.
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone